News & Events about Personalis Inc.
Personalis, Inc. (Nasdaq: PSNL), Cancer Research UKs Cancer Research Horizons, University College London (UCL), and the Francis Crick Institute today announced a collaboration to deploy NeXT Personal, a personalized liquid biopsy-based research assay, for the TRACERx study, a groundbreaking lung...
Market News Video
1 year ago
In trading on Friday, the ARK Genomic Revolution ETF is outperforming other ETFs, up about 5.3% on the day. Components of that ETF showing particular strength include shares of Pacific Biosciences of California, up about 17.9% and shares of Personalis, up about 16.5% on the day...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it will continue its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global science-led biopharmaceutical company, to explore ultra-sensitive molecular residual disease (MRD) measurement...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT...
Personalis, Inc. (Nasdaq: PSNL) today announced a collaboration with UC San Francisco (UCSF) that will deploy a personalized liquid biopsy-based research use only (RUO) assay for a study of patients with colorectal cancer. The research efforts will use Personalis NeXT Personal assay to evaluate...